RecruitingNot ApplicableNCT06666790
DermaSensor Postmarket Surveillance Study
Sponsor
DermaSensor, Inc.
Enrollment
396 participants
Start Date
Oct 8, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
Eligibility
Min Age: 40 Years
Inclusion Criteria3
- Men or women of any ethnic group aged 40 and older
- Primary skin lesion suspicious for melanoma
- Patient is willing and able to read, understand, and sign the informed consent form (ICF)
Exclusion Criteria14
- Lesion is not accessible to the DermaSensor device Handheld Unit and tip (e.g., inside ears, under nails, etc.)
- Lesion is on areas of psoriasis, eczema, acne, or similar inflammatory skin conditions that may impede appropriate DermaSensor device tip placement on the lesion.
- Lesion is greater than 15mm in diameter at the widest point.
- Lesion has a targeted area less than 2.5mm in diameter where the DermaSensor device tip cannot be placed entirely within the border of the targeted area of the lesion.
- Lesion has no contiguous area of at least 2.5mm due to ulceration, erosion or liquid discharge (e.g., blood).
- Lesion is covered by a crust or scale, and lesion surface cannot be cleared of crust or scale such that there is a contiguous area of at least 2.5mm of cleared intact skin that is free of any crust, ulceration, erosion or liquid discharge (e.g., blood).
- Lesion is obstructed by foreign matter that cannot be non-invasively removed (e.g., tattoo, splinter, etc.)
- Lesion is not completely cleared of (i.e., free of any remaining residue) dermoscopy oils, makeup, sunscreen, other topical solutions or powders, markings, and staining treatments (e.g., iodine).
- Lesion is located on acral skin (e.g., sole or palms).
- Lesion is located within 10mm of the eye.
- Lesion is on or adjacent to scars, areas previously biopsied, or areas subjected to any past surgical intervention.
- Lesion is located on mucosal surfaces (e.g. genitals, lips).
- Lesion is located in an area with acute sunburn.
- Dementia or other neurologic, physical or psychological limitation that would prevent the patient from signing informed consent and/or completing any required follow-up visits
Interventions
DEVICEScan with elastic scattering spectroscopy device to assess risk of malignancy
Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06666790
Related Trials
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
NCT067715441 location
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT069566907 locations
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
NCT057046471 location
Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma
NCT053072891 location
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
NCT062987341 location